← Back to headlines
Neurocrine Biosciences Outlines 2026-2027 Plans and Ingrezza Guidance
Neurocrine Biosciences has mapped out its execution plans for 2026 and a 'data-rich' 2027, with its drug Ingrezza projected to guide $2.7B–$2.8B.
21 Mar, 04:03 — 21 Mar, 04:03
Sources
Showing 1 of 1 sources
